ITI-9001 not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ITI-9001 is a self-amplifying RNA (saRNA) immunotherapy formulated with lipid nanoparticles for intramuscular injection. The saRNA encodes a CryJ2-LAMP-1 fusion protein, targeting Japanese Red Cedar (JRC) pollen allergy. ITI-9001 is designed to enhance antigen presentation and stimulate robust immune responses, aiming to reduce allergic symptoms in JCP-sensitive patients.”In the company’s words, NCT07726147 on ClinicalTrials.gov
- Tested for
- Allergen Immunotherapy
- Main trialPhase 1
- “This is a Phase 1, first-in-human clinical trial to test a new treatment called ITI-9001 for people with allergies to Japanese Red Cedar (JRC) pollen-a common cause of seasonal allergies in Japan. The main goals are to find out if ITI-9001 is safe, how well people tolerate it, and whether it can trigger helpful immune responses.”In the company’s words, NCT07726147 on ClinicalTrials.gov
Other drugs for Allergen Immunotherapy
- SHR-1819Hengrui · Phase 3
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
- GR1802Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3
- Rupatifen FumarateFujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Phase 3
- LP-003Longbio Pharma · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 2/3
Coming up1
- Feb 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Feb 2028 | Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026